Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-01-07

FDA Approved: ADVAIR HFA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for Advair HFA (fluticasone propionate and salmeterol xinafoate) submitted by GlaxoSmithKline LLC. The action update…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Advair HFA (fluticasone propionate/salmeterol)

Snippet

SUPPL AP for ADVAIR HFA (FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE)